humburger icon
Two hands holding intersecting puzzle pieces in the air

Corporate Partnerships

Home > Partnerships > Corporate Partnerships

We’re working together with our corporate partners to continually improve the supportive care of people with cancer. Below are some of the opportunities for your company to partner with MASCC:

Sponsor Our Annual Meeting

As the pre-eminent international and interdisciplinary conference on supportive care in cancer, the MASCC/ISOO Annual Meeting is a prime opportunity for your company to showcase products and treatments used to prevent and manage the adverse effects of cancer.

For more information on sponsorship opportunities at the MASCC/ISOO Annual Meeting, please contact Melissa Chin, MASCC Executive Director, at or Ruxandra Nedu, MASCC Associate Director, at

Corporate MASCC Membership

Corporate MASCC membership brings a variety of benefits, including exclusive privileges at the MASCC/ISOO Annual Meeting. These include:

  • Opportunities to meet exclusively with key MASCC opinion leaders
  • Priority in the selection of dates for educational initiatives for MASCC members 
  • Priority in the selection of time slots for satellite symposia held in conjunction with the MASCC/ISOO Annual Meeting
  • Six 2-year MASCC memberships with online access to Supportive Care in Cancer
  • Discounted rates to the MASCC/ISOO Annual Meeting
  • Significantly reduced costs for reviews of corporate-developed educational materials with commentary from MASCC specialists
  • Opportunities to work with key MASCC opinion leaders to look at site-specific symptoms and prevention and management of treatment-induced side effects in cancer
  • Advanced knowledge of the topics and issues facing MASCC members through the work of the study groups

For more information about corporate memberships, please contact

Our Corporate Members:

Napo Pharmaceuticals

Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. For more information about Napo Pharmaceuticals, please visit

Napo Pharmaceuticals logo